The melatonergic agonist agomelatine ameliorates high fat diet-induced obesity in mice through the modulation of the gut microbiome
Metadatos
Mostrar el registro completo del ítemAutor
Díez Echave, Patricia; Vezza, Teresa; Algieri, Francesca; Ruiz Malagón, Antonio Jesús; Hidalgo García, Laura; García García, Federico; Morón Romero, María Rocío; Sánchez Santos, Manuel; Toral, Marta; Romero Pérez, Miguel; Duarte Pérez, Juan Manuel; Garrido Mesa, José; Rodríguez Cabezas, María Elena; Rodríguez Nogales, Alba; Gálvez Peralta, Julio JuanEditorial
Elsevier
Materia
Agomelatine Melatonin Metabolism Metformin Microbiome Obesity
Fecha
2022-07-22Referencia bibliográfica
Patricia Diez-Echave... [et al.]. The melatonergic agonist agomelatine ameliorates high fat diet-induced obesity in mice through the modulation of the gut microbiome, Biomedicine & Pharmacotherapy, Volume 153, 2022, 113445, ISSN 0753-3322, [https://doi.org/10.1016/j.biopha.2022.113445]
Patrocinador
Junta de Andalucia CTS 164; Instituto de Salud Carlos III; European Commission PI19/01058 European CommissionResumen
Background and purpose: Melatonin has shown beneficial effects on obesity, both in humans and experimental
models, via regulating the altered circadian rhythm and thus ameliorating the gut dysbiosis associated with this
metabolic condition. However, its clinical use is limited, mostly due to its short half-life. Agomelatine is an
agonist of the melatonin receptors that could be used to manage obesity and offer a better profile than melatonin.
Experimental approach: Male C57BL/6 mice were fed a high fat diet and orally treated for five weeks with agomelatine,
or melatonin or metformin, used as control drugs. Metabolic profile, inflammatory status, vascular
dysfunction and intestinal microbiota composition were assessed.
Key results: Agomelatine lessened body weight gain, enhanced glucose and lipid metabolisms, and improved
insulin resistance. It also reduced the obesity-associated inflammatory status and endothelial dysfunction,
probably linked to its effect on gut dysbiosis, consisting of the restoration of bacterial populations with key
functions, such as short chain fatty acid production.
Conclusions and implications: Agomelatine can be considered as a novel therapeutic tool for the management of
human obesity and its associated comorbidities.